Phase 2
Completed N=176
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
Open-angle glaucoma · Hypertension · Pigmentary Glaucoma · Pseudoexfoliative Glaucoma
Source: ClinicalTrials.gov NCT00441883 ↗
Enrolled (actual)
176
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 — -6.96; -7.09; -8.20; -6.02 mmHg (milimeters of mercury)
Summary
This study will evaluate the safety and efficacy of PF 03187207.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 |
-6.96; -7.09; -8.20; -6.02; -7.28 | — |
| SECONDARY Change From Baseline in Mean Intraocular Pressure IOP at the Day 7, 14, and 21 Visits |
-6.58; -7.20; -7.85; -5.49; -6.82; -7.20 | — |
| SECONDARY Percentage of Participants With Intraocular Pressure (IOP) Less Than or Equal to 18 mmHg at Any Visit Through Day 28 |
1; 1; 3; 0; 2 | — |
Eligibility Criteria
Inclusion Criteria
-Diagnosis of primary open angle glaucoma (including pigmentary or pseudoexfoliative) or ocular hypertension in one or both eyes
Exclusion Criteria
-Closed or barely open anterior chamber angle or a history of acute angle closure in either eye
Data sourced from ClinicalTrials.gov (NCT00441883). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.